Erlotinib Completed Phase 1 Trials for Tumors, Solid Treatment

IndicationsStatusPurposePhase
CompletedTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT01009073A Study Evaluating ABT-263 With Erlotinib, ABT-263 With Irinotecan, and ABT-263 Monotherapy in Cancer Subjects
NCT00495872Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
NCT00770263Erlotinib and Temsirolimus for Solid Tumors